Pipeline and Commercial Insight: Insomnia - Future of innovative orexin drug class in doubt now available at ReportsandReports

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) August 9, 2010 -- Dallas, TX: ReportsandReports announce it will carry Pipeline and Commercial Insight: Insomnia - Future of innovative orexin drug class in doubt Market Research Report in its Store.

Browse complete Report on: http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-insomnia-future-of-innovative-/

The availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards has intensified competition for both existing and prospective players in the insomnia market. Following the discontinuation of three 5-HT antagonists in late-stage development over 20092010, orexin receptor antagonists now represent the most innovative candidates in the insomnia pipeline.

Scope

• Analysis of insomnia epidemiology, drug recommendations, patient acquisition process and unmet medical needs.
• In depth analysis of historic (200509) and future (201019) seven major market prescription sales dynamics.
• Review of prescription sales data in the Rest of World (200509) and analysis of insomnia epidemiology in Brazil and China.
• Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and country-specific sales forecasts to 2019.

Highlights

In 2019, the value of the seven major insomnia market is forecast to reach $3.5 billion. While growth of the US market is set to be inhibited by further generic erosion from 2011 onwards, Japan will represent the key growth region over the next 10 years.

Sanofi-Aventis's dominance in the insomnia market is under threat due to patent challenges to Ambien CR and Datamonitor expects generic versions of this market leading brand to enter the US over the forecast period. In the absence of pipeline insomnia candidates, Sanofi-Aventis is not expected to regain its market leading status.

Three orexin receptor antagonists are currently under late stage clinical development by two Big Pharma players; GlaxoSmithKline and Merck. While safety observations raised in a Phase III trial of almorexant are of concern to developers, it has potential to become the most successful pipeline candidate.

Reasons to Purchase

• Quantify the current and future size of the insomnia market in the seven major pharmaceutical markets.
• Identify potential licensing opportunities based on product portfolios and anticipated market needs.
• Understand the country-specific impact of key events in the insomnia market during the forecast period 2010 to 2019.

About Us:

Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/

Industry Analysis     market research reports     Pipeline Commercial Insight